CD8A and neoplasm: In their trial, Adriamycin selectively promoted the apoptosis of MDSCs in the spleen, blood, and tumor bed; inhibited the immunosuppressive activity of residual MDSCs; and increased the proportion of CD4+ T cells, CD8+ T cells, NK cells, and their downstream effector factors [161].